“Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe plaque psoriasis” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s134. doi:10.25251/skin.7.supp.134.